DRV/r + RPV QD: Efficacy and Toxicity Reduction
Condition: Human Immunodeficiency VirusInterventions: Drug: RPV + DRV/r; Drug: continue the PI/r-containing HAART.Sponsors: Ospedale L. Sacco – Polo Universitario; Elisa Colella, M.D.; Valentina Di Cristo, M.D.; Massimo Galli, M.D.Recruiting - verified October 2014
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials